department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Opdualag · pharmadog

pharmadog
drugs
Opdualag

drug

patient view →

(nivolumab + relatlimab)

Marketedupdated 2mo ago

by Bristol-Myers Squibb Co

Approved

community read0 votes

all catalysts(0)

nothing on the calendar yet

News(0)

no news has mentioned this drug yet

brand

Opdualag

generic

(nivolumab + relatlimab-rmbw)

indication

Metastatic Melanoma

phase

marketed

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

Data sources

ClinicalTrials.gov

last refreshed 1h ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

🐶 often sniffed alongside

top 6

companyBristol-Myers Squibb Co2 co-mentions · 1 sources
drugOPDIVO1 co-mentions · 1 sources
drugnivolumab1 co-mentions · 1 sources
drugrelatlimab1 co-mentions · 1 sources
tagRecall1 co-mentions · 1 sources
drugOPDIVO QVANTIG1 co-mentions · 1 sources

Trials studying (nivolumab + relatlimab)

phase2Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancerrecruitingn=90
phase2A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumorsrecruitingn=240